Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

OBIO Orchestra BioMed Holdings Inc

Price (delayed)

$2.9

Market cap

$111.11M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.78

Enterprise value

$109.2M

Highlights
The company's gross profit rose by 31% YoY and by 10% QoQ
Orchestra BioMed Holdings's revenue has increased by 30% YoY and by 9% QoQ
The equity has plunged by 71% YoY and by 49% from the previous quarter
Orchestra BioMed Holdings's quick ratio has shrunk by 55% YoY and by 22% QoQ

Key stats

What are the main financial stats of OBIO
Market
Shares outstanding
38.31M
Market cap
$111.11M
Enterprise value
$109.2M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.59
Price to sales (P/S)
38.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
37.84
Earnings
Revenue
$2.89M
Gross profit
$2.67M
Operating income
-$68.8M
Net income
-$66.32M
EBIT
-$66.32M
EBITDA
-$65.25M
Free cash flow
-$54.45M
Per share
EPS
-$1.78
EPS diluted
-$1.78
Free cash flow per share
-$1.42
Book value per share
$0.44
Revenue per share
$0.08
TBVPS
$1.54
Balance sheet
Total assets
$59.05M
Total liabilities
$42.19M
Debt
$16.44M
Equity
$16.86M
Working capital
$36.41M
Liquidity
Debt to equity
0.98
Current ratio
3.35
Quick ratio
3.23
Net debt/EBITDA
0.03
Margins
EBITDA margin
-2,261%
Gross margin
92.6%
Net margin
-2,297.9%
Operating margin
-2,383.9%
Efficiency
Return on assets
-93.8%
Return on equity
-189.3%
Return on invested capital
-159%
Return on capital employed
-152.2%
Return on sales
-2,297.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OBIO stock price

How has the Orchestra BioMed Holdings stock price performed over time
Intraday
0.35%
1 week
9.43%
1 month
1.4%
1 year
-37.23%
YTD
-27.5%
QTD
-32.24%

Financial performance

How have Orchestra BioMed Holdings's revenue and profit performed over time
Revenue
$2.89M
Gross profit
$2.67M
Operating income
-$68.8M
Net income
-$66.32M
Gross margin
92.6%
Net margin
-2,297.9%
The company's gross profit rose by 31% YoY and by 10% QoQ
Orchestra BioMed Holdings's revenue has increased by 30% YoY and by 9% QoQ
OBIO's net income is down by 28% YoY and by 9% QoQ
The operating income has declined by 27% year-on-year and by 7% since the previous quarter

Price vs fundamentals

How does OBIO's price correlate with its fundamentals

Growth

What is Orchestra BioMed Holdings's growth rate over time

Valuation

What is Orchestra BioMed Holdings stock price valuation
P/E
N/A
P/B
6.59
P/S
38.42
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
37.84
Orchestra BioMed Holdings's EPS has decreased by 20% YoY and by 7% from the previous quarter
The equity has plunged by 71% YoY and by 49% from the previous quarter
The price to book (P/B) is 4.6% higher than the last 4 quarters average of 6.3
OBIO's price to sales (P/S) is 53% less than its last 4 quarters average of 81.5
Orchestra BioMed Holdings's revenue has increased by 30% YoY and by 9% QoQ

Efficiency

How efficient is Orchestra BioMed Holdings business performance
OBIO's ROE has dropped by 170% year-on-year and by 40% since the previous quarter
Orchestra BioMed Holdings's return on invested capital has shrunk by 132% YoY and by 14% QoQ
The company's return on assets has shrunk by 91% YoY and by 18% QoQ

Dividends

What is OBIO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OBIO.

Financial health

How did Orchestra BioMed Holdings financials performed over time
The company's total assets is 40% higher than its total liabilities
OBIO's total liabilities has soared by 66% YoY but it is down by 2.4% QoQ
Orchestra BioMed Holdings's quick ratio has shrunk by 55% YoY and by 22% QoQ
Orchestra BioMed Holdings's debt is 2.5% less than its equity
The debt to equity has soared by 96% QoQ
The equity has plunged by 71% YoY and by 49% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.